Zevra Therapeutics, Inc. ZVRA Foreign currency remeasurement (loss) gain on debt
Foreign currency remeasurement (loss) gain on debt at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ForeignCurrencyTransactionGainLossBeforeTax.
The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Zevra Therapeutics, Inc.'s foreign currency remeasurement (loss) gain on debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Zevra Therapeutics, Inc.'s foreign currency remeasurement (loss) gain on debt?
- Zevra Therapeutics, Inc. (ZVRA) reported foreign currency remeasurement (loss) gain on debt of $1.4M in Q1 2026.
- How has Zevra Therapeutics, Inc.'s foreign currency remeasurement (loss) gain on debt changed year-over-year?
- Zevra Therapeutics, Inc.'s foreign currency remeasurement (loss) gain on debt increased by 758.7% year-over-year, from -$213K to $1.4M.
- What does foreign currency remeasurement (loss) gain on debt mean?
- Measures the impact of exchange rate fluctuations on transactions denominated in currencies other than the company's functional currency. It highlights the company's exposure to international market volatility and the effectiveness of its currency risk management strategies.